Suppr超能文献

评估日本肉毒杆菌抗毒素疗法在日本安全性和有效性的回顾性调查。

Retrospective survey to evaluate the safety and efficacy of Japanese botulinum antitoxin therapy in Japan.

作者信息

Mottate Keita, Yokote Hiroyuki, Mori Shigemi, Horita Akira, Miyatsu Yoshinobu, Torii Yasushi, Kozaki Shunji, Iwaki Masaaki, Takahashi Motohide, Ginnaga Akihiro

机构信息

The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), 1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto 860-8568, Japan.

The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), 1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto 860-8568, Japan.

出版信息

Toxicon. 2016 Feb;110:12-8. doi: 10.1016/j.toxicon.2015.11.010. Epub 2015 Nov 22.

Abstract

Japanese botulinum antitoxins have been used for more than 50 years; however, their safety and therapeutic efficacy are not clear. In order to analyze the available data on botulinum antitoxin therapy in Japan, we surveyed published reports about botulism cases in which botulinum antitoxins were used, and retrospectively analyzed the safety and efficacy of the therapy. A total of 134 patients administered botulinum antitoxins were identified from published reports. Two cases of side effects (1.5%) were detected after antitoxin administration, both not fatal. The fatality rate was 9.4%, and more than 70% of the patients showed improvement in their symptoms and better clinical conditions than those not treated with antitoxins. These data suggest that the therapy with Japanese antitoxins is safe and highly effective.

摘要

日本肉毒杆菌抗毒素已使用超过50年;然而,其安全性和治疗效果尚不清楚。为了分析日本肉毒杆菌抗毒素治疗的现有数据,我们调查了已发表的使用肉毒杆菌抗毒素的肉毒中毒病例报告,并回顾性分析了该治疗的安全性和有效性。从已发表的报告中确定了总共134例接受肉毒杆菌抗毒素治疗的患者。抗毒素给药后检测到2例副作用(1.5%),均非致命。死亡率为9.4%,超过70%的患者症状有所改善,临床状况比未接受抗毒素治疗的患者更好。这些数据表明,日本抗毒素治疗是安全且高效的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验